Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?

3 new Ebola therapies will be tested; Liberia lifts emergency

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!
Medical workers will test the effectiveness of three new potential Ebola therapies at clinics run by the nongovernmental organization Medecins Sans Frontieres (Doctors Without Borders).
Medical workers will test the effectiveness of three new potential Ebola therapies at clinics run by the nongovernmental organization Medecins Sans Frontieres (Doctors Without Borders).
Zoom Dosso

Medical teams plan to start three clinical trials in the fight against the Ebola virus next month, administering the drugs at treatment centers run by Doctors Without Borders in West Africa. Two of the therapies involve antiviral drugs.

Two of the clinical trials will be conducted in Guinea and Liberia; the location for a third hasn't been selected, according to Doctors Without Borders. The group says it hopes to quickly find another tool to use against an outbreak that has killed more than 5,000 people.

NPR's Richard Harris reports:

"Scientists working with the World Health Organization have a shortlist of drugs that are ready for testing.

"They include favipiravir, which is used in Japan to treat the flu, and brincidofovir, which is an experimental antiviral drug being developed in the United States. There's not much evidence that these drugs will work against Ebola, but they appear to be safe — and if they do work, there should be an adequate supply.

"Doctors also plan to test blood and blood plasma in a scientific setting to see whether these products can help sick people fight off the Ebola virus."

In an interview with Morning Edition, Richard notes that two other drugs that have shown good results in tests on monkeys — ZMapp and Tekmira Ebola — will not be included in the trials, mainly because there isn't enough of a supply.

by NPR

"It wouldn't be surprising to see these two drugs tested next year," Richard says, "just not in this first round."

He added that contrary to most clinical trials, all of the people in the planned studies will receive the experimental therapies.

"There will be no comparison group," Richard says, noting that the approach could limit the information scientists get from the study.

News of the new tests comes as Liberia's President Ellen Johnson Sirleaf announces that she is lifting the state of emergency that she declared in early August.

"This is not because the fight against Ebola is over," Sirleaf said.

Noting that many of the measures introduced as part of the fight against the virus will remain in place, she also applauded her country's progress. As we reported last week, the World Health Organization has been seeing a decline in new Ebola cases in Liberia. "I am pleased to announce that the curfew is extended to midnight, except those in proximity to hot spots," Sirleaf said, adding that markets and schools closed by the emergency can now reopen. Copyright 2019 NPR. To see more, visit https://www.npr.org.